Akari Therapeutics Plc Sponsored ADR Stock News

BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the pres...

Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari's commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1 Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari's commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1

PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body

BOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari, participated in the Virtual Investor “What's Your Story” Summer Spotlight...

Access the “What This Means” segment here BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced it recently participated in a Virtual Investor “What This Means” segment. For the segment, Abizer Gaslightwala...

Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms

Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates

BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29...